Newest
PEBO ▼ sold $76K · Augenstein Mark filed 1d agoBBT ▲ bought $105K · Hollister Thomas J filed 2d agoBBT ▼ sold $20K · Eagan John Buckley filed 2d agoGS ▼ sold $60K · LESLIE ERICKA T filed 2d agoGS ▼ sold $163K · LESLIE ERICKA T filed 2d agoMSCI ▼ sold $1.5M · Gutowski Robert J. filed 2d agoGL ▼ sold $2.2M · MAJORS MICHAEL CLAY filed 2d agoPHR ▲ bought $362 · Linetsky David filed 2d agoPHR ▲ bought $320 · Linetsky David filed 2d agoRVI ▲ bought $23K · Whitney Meredith filed 2d agoLEO ▲ bought $369K · Saba Capital Management, L.P. filed 2d agoPG ▼ sold $5.7M · Jejurikar Shailesh filed 2d agoICLR ▼ sold $10K · Lyons Emer filed 2d agoICLR ▼ sold $10K · Lyons Emer filed 2d agoICLR ▼ sold $8K · Lyons Emer filed 2d agoICLR ▼ sold $15K · Lyons Emer filed 2d agoICLR ▼ sold $8K · Lyons Emer filed 2d agoPG ▼ sold $698K · Gama Paul filed 2d ago

Insider / AMETEK INC/

McClain Gretchen W

Director at AMETEK INC/

Company
AMETEK INC/
Tickers
BAH, AME
First filing on record
March 18, 2026
Latest trade on record
August 4, 2026
SEC filings
EDGAR ↗

McClain Gretchen W, Director at AMETEK INC/, has disclosed 3 transactions in BAH, AME since March 18, 2026: 0 purchases (0 open-market buys) and 0 sales, worth about $202K at the reported prices. The latest was filed August 6, 2026, 2 days after the trade.

Last updated August 6, 2026 · Source: SEC EDGAR Form 4 filings

Transactions
3
Open-market buys
0
Sales
0
Avg. disclosure lag
0.7d

Trading in charts

Trade timeline

When does this person trade, how big, and in which direction? Every trade in the last 12 months.

Bought (above the line)Sold (below the line)Other transaction
Oct 25NovDecJan 26FebMarAprMayJunJulAugSep
Oct 25NovDecJan 26FebMarAprMayJunJulAugSep

In the last 12 months McClain Gretchen W reported 3 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.

Reporting lag

Does this person report on time? One bar per filing against the Form 4 deadline.

On timeLate
Form 4 deadlineoldest filingnewest

0 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).

What kind of transactions

Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.

Rows by Form 4 transaction code
CodeMeaningRowsSharesValue
AGrant or award25,639$202K
JOther acquisition or disposal152—
Rows by year of the trade
YearRowsBoughtSold
2026300

Transactions

Download AME trades (CSV)125 rows · 40 KB · every filer in this ticker, this insider included · all downloads

SecuritySideTrade dateDisclosedLagSharesPriceValueFlagsSourceShare
BAHOther AAugust 4, 2026August 6, 20262d4,689——Form 4 ↗
AMEOther JMarch 18, 2026March 18, 20260d52——Form 4 ↗
AMEOther AMarch 18, 2026March 18, 20260d950$213$202KForm 4 ↗

Filings

FiledFormAccessionRowsStatusSource
August 6, 2026Form 40001443646-26-0000511publishedEDGAR ↗
March 18, 2026Form 40001037868-26-0000772publishedEDGAR ↗

Other insiders at AMETEK INC/

Everyone on file, with contracts and lobbying under the company's name: AMETEK INC/.

Guides for this page

Sources and method

Official sources behind this page
SourceFilingsRowsFirst filedNewest filedRead the originals
SEC EDGAR, Form 423March 18, 2026August 6, 2026Form 4 list on EDGAR

Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.

Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.

Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.